{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:24:23Z","timestamp":1792783463877,"version":"4.5.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T00:00:00Z","timestamp":1772409600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T00:00:00Z","timestamp":1772409600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"VLAIO","award":["HBC.2019.2923"],"award-info":[{"award-number":["HBC.2019.2923"]}],"id":[{"id":"https:\/\/ror.org\/032xdry56","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drug Deliv. and Transl. Res."],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1007\/s13346-026-02062-4","type":"journal-article","created":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T17:09:27Z","timestamp":1772471367000},"page":"3702-3713","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Impact of solvent choice during microfluidic manufacture on the in vivo performance of liposomal doxorubicin"],"prefix":"10.1007","volume":"16","author":[{"given":"Sarah","family":"Lindsay","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ren\u00e9","family":"Holm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanket","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yvonne","family":"Perrie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,2]]},"reference":[{"key":"2062_CR1","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines10061259","author":"CY Lee","year":"2022","unstructured":"Lee CY, et al. Fabrication of doxorubicin-loaded lipid-based nanocarriers by microfluidic rapid mixing. Biomedicines. 2022. https:\/\/doi.org\/10.3390\/biomedicines10061259.","journal-title":"Biomedicines"},{"key":"2062_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2020.119566","volume":"586","author":"CB Roces","year":"2020","unstructured":"Roces CB, et al. Rapid scale-up and production of active-loaded PEGylated liposomes. Int J Pharm. 2020;586:119566.","journal-title":"Int J Pharm"},{"key":"2062_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2022.120574","volume":"300","author":"B Sheikholeslami","year":"2022","unstructured":"Sheikholeslami B, et al. Exploring the impact of physicochemical properties of liposomal formulations on their in vivo fate. Life Sci. 2022;300:120574.","journal-title":"Life Sci"},{"key":"2062_CR4","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.jconrel.2014.03.053","volume":"190","author":"AC Anselmo","year":"2014","unstructured":"Anselmo AC, Mitragotri S. An overview of clinical and commercial impact of drug delivery systems. J Control Release. 2014;190:15\u201328.","journal-title":"J Control Release"},{"issue":"5","key":"2062_CR5","doi-asserted-by":"publisher","first-page":"419","DOI":"10.2165\/00003088-200342050-00002","volume":"42","author":"A Gabizon","year":"2003","unstructured":"Gabizon A, Shmeeda H, Barenholz Y. Pharmacokinetics of pegylated liposomal doxorubicin. Clin Pharmacokinet. 2003;42(5):419\u201336.","journal-title":"Clin Pharmacokinet"},{"issue":"18","key":"2062_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmc.2020.115556","volume":"28","author":"Z Ka\u017amierczak","year":"2020","unstructured":"Ka\u017amierczak Z, et al. Endocytosis in cellular uptake of drug delivery vectors: molecular aspects in drug development. Bioorg Med Chem. 2020;28(18):115556.","journal-title":"Bioorg Med Chem"},{"key":"2062_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2020.119266","volume":"582","author":"C Webb","year":"2020","unstructured":"Webb C, et al. Using microfluidics for scalable manufacturing of nanomedicines from bench to GMP: a case study using protein-loaded liposomes. Int J Pharm. 2020;582:119266.","journal-title":"Int J Pharm"},{"key":"2062_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2020.07.002","author":"S Shah","year":"2020","unstructured":"Shah S, et al. Liposomes: advancements and innovation in the manufacturing process. Adv Drug Deliv Rev. 2020. https:\/\/doi.org\/10.1016\/j.addr.2020.07.002.","journal-title":"Adv Drug Deliv Rev"},{"key":"2062_CR9","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.nano.2019.02.019","volume":"18","author":"VM Shah","year":"2019","unstructured":"Shah VM, et al. Liposomes produced by microfluidics and extrusion: a comparison for scale-up purposes. Nanomedicine Nanotechnol Biol Med. 2019;18:146\u201356.","journal-title":"Nanomedicine Nanotechnol Biol Med"},{"key":"2062_CR10","doi-asserted-by":"crossref","unstructured":"Perrie Y, et al. Manufacturing methods for liposome adjuvants, in vaccine adjuvants: methods and protocols. In: Fox CB, editor. Springer New York: New York, NY; 2017. p. 127\u2013144.","DOI":"10.1007\/978-1-4939-6445-1_9"},{"issue":"5","key":"2062_CR11","doi-asserted-by":"publisher","first-page":"3263","DOI":"10.3390\/ijms12053263","volume":"12","author":"C-Y Lee","year":"2011","unstructured":"Lee C-Y, et al. Microfluidic mixing: a review. Int J Mol Sci. 2011;12(5):3263\u201387.","journal-title":"Int J Mol Sci"},{"key":"2062_CR12","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.jconrel.2022.02.017","volume":"344","author":"M Maeki","year":"2022","unstructured":"Maeki M, et al. Microfluidic technologies and devices for lipid nanoparticle-based RNA delivery. J Control Release. 2022;344:80\u201396.","journal-title":"J Control Release"},{"key":"2062_CR13","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics16091159","author":"S Lindsay","year":"2024","unstructured":"Lindsay S, et al. Can we simplify liposome manufacturing using a complex DoE approach? Pharmaceutics. 2024. https:\/\/doi.org\/10.3390\/pharmaceutics16091159.","journal-title":"Pharmaceutics"},{"issue":"1","key":"2062_CR14","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1208\/s12248-016-9958-2","volume":"19","author":"W Yuan","year":"2017","unstructured":"Yuan W, et al. Development of a flow-through USP-4 apparatus drug release assay to evaluate doxorubicin liposomes. AAPS J. 2017;19(1):150\u201360.","journal-title":"AAPS J"},{"key":"2062_CR15","doi-asserted-by":"publisher","DOI":"10.1002\/bmc.3863","author":"S Mazzucchelli","year":"2017","unstructured":"Mazzucchelli S, et al. Lc-ms\/ms method development for quantification of doxorubicin and its metabolite 13-hydroxy doxorubicin in mice biological matrices: application to a pharmaco-delivery study. Biomed Chromatogr. 2017. https:\/\/doi.org\/10.1002\/bmc.3863.","journal-title":"Biomed Chromatogr"},{"issue":"2","key":"2062_CR16","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.jchromb.2004.04.030","volume":"808","author":"RD Arnold","year":"2004","unstructured":"Arnold RD, Slack JE, Straubinger RM. Quantification of doxorubicin and metabolites in rat plasma and small volume tissue samples by liquid chromatography\/electrospray tandem mass spectroscopy. J Chromatogr B Analyt Technol Biomed Life Sci. 2004;808(2):141\u201352.","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"2062_CR17","doi-asserted-by":"crossref","unstructured":"Devrim B, Bozk\u0131r A. Chapter 7 - nanocarriers and their potential application as antimicrobial drug delivery, in nanostructures for antimicrobial therapy. In: Ficai A, Grumezescu AM, editors. Elsevier; 2017. p. 169\u2013202.","DOI":"10.1016\/B978-0-323-46152-8.00007-X"},{"issue":"1","key":"2062_CR18","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1007\/s12668-022-00941-x","volume":"12","author":"V Andra","year":"2022","unstructured":"Andra V, et al. A comprehensive review on novel liposomal methodologies, commercial formulations, clinical trials and patents. Bionanoscience. 2022;12(1):274\u201391.","journal-title":"Bionanoscience"},{"key":"2062_CR19","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.addr.2018.06.024","volume":"131","author":"S M\u00fchlebach","year":"2018","unstructured":"M\u00fchlebach S. Regulatory challenges of nanomedicines and their follow-on versions: a generic or similar approach? Adv Drug Deliv Rev. 2018;131:122\u201331.","journal-title":"Adv Drug Deliv Rev"},{"issue":"12","key":"2062_CR20","doi-asserted-by":"publisher","first-page":"903","DOI":"10.2165\/00002018-200124120-00004","volume":"24","author":"DN Waterhouse","year":"2001","unstructured":"Waterhouse DN, et al. A comparison of liposomal formulations of doxorubicin with drug administered in free form. Drug Saf. 2001;24(12):903\u201320.","journal-title":"Drug Saf"},{"issue":"1","key":"2062_CR21","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1002\/jps.23795","volume":"103","author":"D Cipolla","year":"2014","unstructured":"Cipolla D, et al. Development and characterization of an in vitro release assay for liposomal ciprofloxacin for inhalation. J Pharm Sci. 2014;103(1):314\u201327.","journal-title":"J Pharm Sci"},{"issue":"8","key":"2062_CR22","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.3109\/03639045.2014.954582","volume":"41","author":"H Shibata","year":"2015","unstructured":"Shibata H, et al. Investigation of factors affecting in vitro doxorubicin release from PEGylated liposomal doxorubicin for the development of in vitro release testing conditions. Drug Dev Ind Pharm. 2015;41(8):1376\u201386.","journal-title":"Drug Dev Ind Pharm"},{"issue":"1","key":"2062_CR23","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1080\/21691401.2023.2247036","volume":"51","author":"S Pande","year":"2023","unstructured":"Pande S. Liposomes for drug delivery: review of vesicular composition, factors affecting drug release and drug loading in liposomes. Artif Cells Nanomed Biotechnol. 2023;51(1):428\u201340.","journal-title":"Artif Cells Nanomed Biotechnol"},{"issue":"5","key":"2062_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2022.e09394","volume":"8","author":"H Nsairat","year":"2022","unstructured":"Nsairat H, et al. Liposomes: structure, composition, types, and clinical applications. Heliyon. 2022;8(5):e09394.","journal-title":"Heliyon"},{"issue":"7","key":"2062_CR25","doi-asserted-by":"publisher","first-page":"2419","DOI":"10.1039\/D2BM01703B","volume":"11","author":"Y Matsuura-Sawada","year":"2023","unstructured":"Matsuura-Sawada Y, et al. Controlling lamellarity and physicochemical properties of liposomes prepared using a microfluidic device. Biomater Sci. 2023;11(7):2419\u201326.","journal-title":"Biomater Sci"},{"key":"2062_CR26","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics11120653","author":"C Webb","year":"2019","unstructured":"Webb C, et al. The impact of solvent selection: strategies to guide the manufacturing of liposomes using microfluidics. Pharmaceutics. 2019. https:\/\/doi.org\/10.3390\/pharmaceutics11120653.","journal-title":"Pharmaceutics"},{"issue":"3","key":"2062_CR27","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/S0304-4157(96)00010-X","volume":"1286","author":"FJ Weber","year":"1996","unstructured":"Weber FJ, de Bont JAM. Adaptation mechanisms of microorganisms to the toxic effects of organic solvents on membranes. Biochimica et Biophysica Acta (BBA) - Rev Biomembr. 1996;1286(3):225\u201345.","journal-title":"Biochimica et Biophysica Acta (BBA) - Rev Biomembr"},{"key":"2062_CR28","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.ijpharm.2018.11.060","volume":"556","author":"N Forbes","year":"2019","unstructured":"Forbes N, et al. Rapid and scale-independent microfluidic manufacture of liposomes entrapping protein incorporating in-line purification and at-line size monitoring. Int J Pharm. 2019;556:68\u201381.","journal-title":"Int J Pharm"},{"issue":"8","key":"2062_CR29","doi-asserted-by":"publisher","first-page":"2166","DOI":"10.1039\/D3NA01073B","volume":"6","author":"M Maeki","year":"2024","unstructured":"Maeki M, et al. Understanding the effects of ethanol on the liposome bilayer structure using microfluidic-based time-resolved small-angle X-ray scattering and molecular dynamics simulations. Nanoscale Adv. 2024;6(8):2166\u201376.","journal-title":"Nanoscale Adv"},{"key":"2062_CR30","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics14030543","author":"D Lombardo","year":"2022","unstructured":"Lombardo D, Kiselev MA. Methods of liposomes preparation: formation and control factors of versatile nanocarriers for biomedical and nanomedicine application. Pharmaceutics. 2022. https:\/\/doi.org\/10.3390\/pharmaceutics14030543.","journal-title":"Pharmaceutics"},{"issue":"11","key":"2062_CR31","doi-asserted-by":"publisher","first-page":"4696","DOI":"10.1002\/jps.21358","volume":"97","author":"DC Drummond","year":"2008","unstructured":"Drummond DC, et al. Pharmacokinetics and in vivo drug release rates in liposomal nanocarrier development. J Pharm Sci. 2008;97(11):4696\u2013740.","journal-title":"J Pharm Sci"},{"issue":"2","key":"2062_CR32","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics14020254","volume":"14","author":"M Ibrahim","year":"2022","unstructured":"Ibrahim M, et al. Encapsulation, release, and cytotoxicity of doxorubicin loaded in liposomes, micelles, and metal-organic frameworks: a review. Pharmaceutics. 2022;14(2):254.","journal-title":"Pharmaceutics"},{"issue":"7","key":"2062_CR33","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1248\/bpb.18.1020","volume":"18","author":"A Nagayasu","year":"1995","unstructured":"Nagayasu A, Shimooka T, Kiwada H. Effect of vesicle size on in vivo release of daunorubicin from hydrogenated egg phosphatidylcholine-based liposomes into blood circulation. Biol Pharm Bull. 1995;18(7):1020\u20133.","journal-title":"Biol Pharm Bull"},{"key":"2062_CR34","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.ejps.2018.11.019","volume":"128","author":"B Fl\u00fchmann","year":"2019","unstructured":"Fl\u00fchmann B, et al. Nanomedicines: the magic bullets reaching their target? Eur J Pharm Sci. 2019;128:73\u201380.","journal-title":"Eur J Pharm Sci"},{"issue":"1","key":"2062_CR35","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1208\/s12248-013-9533-z","volume":"16","author":"H Schellekens","year":"2014","unstructured":"Schellekens H, et al. How to regulate nonbiological complex drugs (NBCD) and their follow-on versions: points to consider. AAPS J. 2014;16(1):15\u201321.","journal-title":"AAPS J"},{"key":"2062_CR36","doi-asserted-by":"crossref","unstructured":"Merino M, Zalba S, Garrido MJ. Immunoliposomes in clinical oncology: State of the art and future perspectives. Journal of Controlled Release. 2018;275:162-176.","DOI":"10.1016\/j.jconrel.2018.02.015"}],"container-title":["Drug Delivery and Translational Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13346-026-02062-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13346-026-02062-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13346-026-02062-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T13:57:37Z","timestamp":1790603857000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13346-026-02062-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,2]]},"references-count":36,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["2062"],"URL":"https:\/\/doi.org\/10.1007\/s13346-026-02062-4","relation":{},"ISSN":["2190-393X","2190-3948"],"issn-type":[{"value":"2190-393X","type":"print"},{"value":"2190-3948","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,2]]},"assertion":[{"value":"28 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The animal study was approved by the animal ethics committee of the institution in accordance with the European convention for the protection of vertebrate animals used for experimental and other scientific purposes (ETS no. 123) and followed the Belgian Royal Decree of May 29, 2013, for the protection of laboratory animals.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The data underpinning this publication is openly available from the University of Strathclyde KnowledgeBase at\n                      \n                      .","order":3,"name":"Ethics","label":"Data availability","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":4,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}]}}